SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ADARx Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☑ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Zhen Li	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially	5	Sole Voting Power 4,939,795.00

Owned by Each Reporting Person With:	6	Shared Voting Power 5,911,763.00
	7	Sole Dispositive Power 4,939,795.00
	8	Shared Dispositive Power 5,911,763.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 10,851,558.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.7 %
12		Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: (1) Amount reported in Row (9) consists of (i) 4,939,795 shares of Common Stock (as defined herein) subject to options held by the Reporting Person that are exercisable within 60 days of September 30, 2026, (ii) 5,861,199 shares of Common Stock held by the Titanium Boulder Irrevocable Trust dated July 11, 2020 (the "Titanium Trust"), for which the Reporting Person and her spouse serve as trustees, and (iii) 50,564 shares of Common Stock subject to options held by the Reporting Person's spouse that are exercisable within 60 days of September 30, 2026. The Reporting Person and her spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust. The Reporting Person disclaims beneficial ownership of the shares of Common Stock subject to options held by the Reporting Person's spouse. (2) Percent of class represented by amount in Row (11) is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026, (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by the Reporting Person within 60 days of September 30, 2026, and (iii) 50,564 shares of Common Stock issuable upon exercise of options held by the Reporting Person's spouse within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

SCHEDULE 13G

Item 1.

(a) Name of issuer:

ADARx Pharmaceuticals, Inc.

(b) Address of issuer's principal executive offices:

5871 Oberlin Drive, Suite 200, San Diego, CA 92121

Item 2.

(a) Name of person filing:

This statement is being filed by Zhen Li (the "Reporting Person").

(b) Address or principal business office or, if none, residence:

The principal business address of the Reporting Person is c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121.

(c) Citizenship:

The Reporting Person is a citizen of the United States.

(d) Title of class of securities:

Common Stock, $0.0001 par value per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) As of September 30, 2026, the Reporting Person may be deemed the beneficial owner of 10,851,558 shares of Common Stock, $0.0001 par value per share (the "Common Stock"). This amount consists of (i) 4,939,795 shares of Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of September 30, 2026, (ii) 5,861,199 shares of Common Stock held by the Titanium Trust, for which the Reporting Person and her spouse serve as trustees, and (iii) 50,564 shares of Common Stock subject to options held by the Reporting Person's spouse that are exercisable within 60 days of September 30, 2026. The Reporting Person and her spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust. The Reporting Person disclaims beneficial ownership of the shares of Common Stock subject to options held by the Reporting Person's spouse.

Percent of class:

(b) As of September 30, 2026, the Reporting Person may be deemed to beneficially own approximately 9.7% of the shares of Common Stock outstanding. The foregoing percentage is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026, (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by the Reporting Person within 60 days of September 30, 2026, and (iii) 50,564 shares of Common Stock issuable upon exercise of options held by the Reporting Person's spouse within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Exchange Act. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

4,939,795.00

(ii) Shared power to vote or to direct the vote:

5,911,763.00

(iii) Sole power to dispose or to direct the disposition of:

4,939,795.00

(iv) Shared power to dispose or to direct the disposition of:

5,911,763.00

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

The Titanium Trust has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the shares of Common Stock outstanding.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Zhen Li

Signature: /s/ Zhen Li
Name/Title: Zhen Li
Date: 11/13/2026